Clostridioides difficile Infection: Targeting an Unwelcome and Persistent Threat

An integrated symposium, with an esteemed panel of experts, discussed the burden and treatment approaches for Clostridioides difficile infection (CDI). The session took place on 17th April 2023 as part 33rd European Congress Clinical Microbiology Infectious Diseases (ECCMID) in Copenhagen, Denmark. was co-chaired by Mark Wilcox, Head Research & Development Infection Lead at Leeds Teaching Hospitals NHS Trust, UK, Professor Medical University Leeds, UK; Anne Gonzales-Luna, Assistant Houston College Pharmacy, Texas, USA. Sarah Tschudin-Sutter, Division Hospital Epidemiology Basel, Switzerland, explored changing landscape CDI, including epidemiology surveillance infection, to diagnosis. John Coia, Emeritus Institute Regional Health Research, South Denmark, Honorary Fellow Glasgow University, Esther Calbo, Disease Universitari Mútua de Terrassa, Spain, gave overview recurrent dysbiosis role mortality risk, importance targeting recurrence. Calbo also presented interactive case study that allowed audience members engage review patient presented. faculty how approach assessment achieve best outcome case. Benoît Guery, Associate Centre Hospitalier Universitaire Vaudois, data from EXTEND study, which extended-pulse dosing regimens antibiotics (fidaxomicin) CDI.